CÁNCER DE MAMA
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Barcelona, EspañaPublikationen in Zusammenarbeit mit Forschern von Institut d'Investigacions Biomèdiques August Pi i Sunyer (8)
2023
-
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry
Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159
2021
-
C3G downregulation induces the acquisition of a mesenchymal phenotype that enhances aggressiveness of glioblastoma cells
Cell Death and Disease, Vol. 12, Núm. 4
-
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499
2019
-
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125
2017
-
Predictive and prognostic brain metastases assessment in luminal breast cancer patients: FN14 and GRP94 from diagnosis to prophylaxis
Frontiers in Oncology, Vol. 7, Núm. DEC
-
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population
Stem Cell Reports, Vol. 8, Núm. 5, pp. 1392-1407
2015
-
FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies
Oncotarget, Vol. 6, Núm. 42, pp. 44254-44273
2008
-
Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer
Cancer Treatment Reviews, Vol. 34, Núm. 8, pp. 701-709